{"nctId":"NCT00735644","briefTitle":"Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines","startDateStruct":{"date":"2008-08"},"conditions":["Japanese Encephalitis","Hepatitis A"],"count":1200,"armGroups":[{"label":"JE-CV GPO MBP (Lot 1)","type":"EXPERIMENTAL","interventionNames":["Biological: Japanese encephalitis vaccine"]},{"label":"JE-CV GPO MBP (Lot 2)","type":"EXPERIMENTAL","interventionNames":["Biological: Japanese encephalitis vaccine"]},{"label":"JE-CV GPO MBP (Lot 3)","type":"EXPERIMENTAL","interventionNames":["Biological: Japanese encephalitis vaccine"]},{"label":"JE-CV WRAIR (Group 4)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Japanese encephalitis vaccine (Acambis)"]},{"label":"Hepatitis A (Group 5)","type":"SHAM_COMPARATOR","interventionNames":["Biological: Hepatitis A vaccine"]}],"interventions":[{"name":"Japanese encephalitis vaccine","otherNames":["ChimeriVax™-JE"]},{"name":"Japanese encephalitis vaccine","otherNames":["ChimeriVax™-JE"]},{"name":"Japanese encephalitis vaccine","otherNames":["ChimeriVax™-JE"]},{"name":"Japanese encephalitis vaccine (Acambis)","otherNames":[]},{"name":"Hepatitis A vaccine","otherNames":["Avaxim® 80U Pediatric"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria :\n\n* Aged 12 to 18 months on the day of inclusion.\n* In good general health, without significant medical history.\n* Provision of informed consent form signed by at least one parent or other legally acceptable representative, and by at least one independent witness if required by local regulations.\n* Subject and parent/legally acceptable representative able to attend all scheduled visits and comply with all trial procedures.\n* Completion of vaccinations according to the national immunization schedule.\n\nExclusion Criteria :\n\n* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the trial vaccination.\n* Planned participation in another clinical trial during the present trial period.\n* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy.\n* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to a vaccine containing any of the same substances.\n* Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator.\n* Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of the immune response.\n* Administration of any anti-viral within 2 months preceding V01.\n* History of central nervous system disorder or disease, including seizures.\n* Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia.\n* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.\n* Planned receipt of any vaccine in the 4 weeks following any trial vaccination.\n* Personal human immunodeficiency virus seropositivity in the blood sample taken at screening.\n* Receipt of any JE vaccine or hepatitis A vaccine.\n* Previous vaccination against flavivirus disease.\n* History of flavivirus infection (confirmed either clinically, serologically or microbiologically)\n* Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating intramuscular vaccination.\n* Febrile illness (temperature ≥38°C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment.","healthyVolunteers":true,"sex":"ALL","minimumAge":"12 Months","maximumAge":"18 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Seroconversion to Vaccine Antigens Following Vaccination With JE-CV by GPO MBP Lots","description":"Anti-Japanese encephalitis chimeric virus vaccine antibodies were measured using the 50% plaque reduction neutralization test (PRNT50). Seroconversion was defined as participants with a pre-vaccination titer \\<10 1/dil and post-vaccination titer ≥ 10 1/dil, or participants with pre-vaccination titer ≥ 10 1/dil and 4-fold increase from pre- to post-vaccination.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"282","spread":null},{"groupId":"OG001","value":"262","spread":null},{"groupId":"OG002","value":"267","spread":null},{"groupId":"OG003","value":"185","spread":null},{"groupId":"OG004","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers Against the Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Antigens Before and Following Vaccination With a JE-CV by GPO MBP Lot or Walter Reed Army Institute of Research (WRAIR) JE-CV","description":"Anti-Japanese Encephalitis Chimeric Virus antibodies were measured using the 50% plaque reduction neutralization test (PRNT50) assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.17","spread":null},{"groupId":"OG001","value":"5.08","spread":null},{"groupId":"OG002","value":"5.19","spread":null},{"groupId":"OG003","value":"5.09","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"212","spread":null},{"groupId":"OG001","value":"167","spread":null},{"groupId":"OG002","value":"188","spread":null},{"groupId":"OG003","value":"212","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Seroprotection to Japanese Encephalitis Chimeric Virus Antigens Before and Following Vaccination With a JE-CV by GPO MBP Lot or WRAIR JE-CV","description":"Anti-Japanese encephalitis chimeric virus vaccine antibodies were measured using the PRNT50 assay. Seroprotection was defined as the proportion of subjects with a JE CV virus PRNT50 neutralizing antibody titer ≥10 1/dilution (dil).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"297","spread":null},{"groupId":"OG001","value":"269","spread":null},{"groupId":"OG002","value":"276","spread":null},{"groupId":"OG003","value":"190","spread":null},{"groupId":"OG004","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titers Ratios Against the Japanese Encephalitis Chimeric Virus (JE-CV) Antigen Following Vaccination With One of the JE-CV by GPO MBP Lots or WRAIR JE-CV Vaccine","description":"Anti Japanese encephalitis chimeric virus antibodies were measured using the PRNT50 assay.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41.1","spread":null},{"groupId":"OG001","value":"32.9","spread":null},{"groupId":"OG002","value":"36.6","spread":null},{"groupId":"OG003","value":"42.2","spread":null},{"groupId":"OG004","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Vaccination With a Japanese Encephalitis Chimeric Virus Vaccine (JE- CV) by GPO MBP Lot or WRAIR JE-CV, or Hepatitis A Vaccine.","description":"Solicited injection site: Tenderness, Erythema, and Swelling; Solicited systemic reactions: Fever (Temperature), Vomiting, Crying Abnormal, Drowsiness, Appetite Lost, and Irritability. Grade 3 injection site: Tenderness, cries when injected limb is moved or the movement of injected limb is reduced; Erythema and Swelling ≥5 cm. Grade 3 systemic reactions: Fever, temperature \\>39.5˚C; Vomiting, ≥6 episodes per 24 hours or requiring parenteral hydration; Crying Abnormal, \\>3 hours; Drowsiness, sleeping most of the time or difficult to wake up; Appetite Lost, refuses ≥3 or most feeds/meals; and Irritability, inconsolable.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"59","spread":null},{"groupId":"OG002","value":"67","spread":null},{"groupId":"OG003","value":"59","spread":null},{"groupId":"OG004","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"63","spread":null},{"groupId":"OG002","value":"87","spread":null},{"groupId":"OG003","value":"54","spread":null},{"groupId":"OG004","value":"26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"21","spread":null},{"groupId":"OG003","value":"13","spread":null},{"groupId":"OG004","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"62","spread":null},{"groupId":"OG002","value":"64","spread":null},{"groupId":"OG003","value":"48","spread":null},{"groupId":"OG004","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"57","spread":null},{"groupId":"OG002","value":"53","spread":null},{"groupId":"OG003","value":"39","spread":null},{"groupId":"OG004","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"54","spread":null},{"groupId":"OG002","value":"50","spread":null},{"groupId":"OG003","value":"41","spread":null},{"groupId":"OG004","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null},{"groupId":"OG001","value":"53","spread":null},{"groupId":"OG002","value":"53","spread":null},{"groupId":"OG003","value":"38","spread":null},{"groupId":"OG004","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"71","spread":null},{"groupId":"OG002","value":"74","spread":null},{"groupId":"OG003","value":"57","spread":null},{"groupId":"OG004","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"2","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"79","spread":null},{"groupId":"OG002","value":"79","spread":null},{"groupId":"OG003","value":"65","spread":null},{"groupId":"OG004","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Serological Status of Flavivirus Infection at Baseline (Before) Vaccination With a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) or Hepatitis A Vaccine.","description":"Flavivirus (FV) positive was defined as anti-JE against homologous virus strain ≥10 l/dil or anti dengue against at least one serotype ≥10 l/dil. FV negative was defined as anti-JE against homologous virus strain \\<10 l/dil and anti-dengue against the 4 serotypes \\<10 l/dilution.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"32","spread":null},{"groupId":"OG003","value":"15","spread":null},{"groupId":"OG004","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"265","spread":null},{"groupId":"OG001","value":"266","spread":null},{"groupId":"OG002","value":"249","spread":null},{"groupId":"OG003","value":"176","spread":null},{"groupId":"OG004","value":"84","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"19","spread":null},{"groupId":"OG002","value":"28","spread":null},{"groupId":"OG003","value":"14","spread":null},{"groupId":"OG004","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"26","spread":null},{"groupId":"OG003","value":"11","spread":null},{"groupId":"OG004","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"18","spread":null},{"groupId":"OG002","value":"27","spread":null},{"groupId":"OG003","value":"12","spread":null},{"groupId":"OG004","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"13","spread":null},{"groupId":"OG003","value":"7","spread":null},{"groupId":"OG004","value":"8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":302},"commonTop":["Irritability","Upper respiratory tract infection","Appetite Lost","Injection site erythema","Injection site tenderness"]}}}